Henrik Wegener

DuPont Nutrition Biosciences ApS is engaged in the production of food enzymes, products and pharmaceutical grade excipients for food products. It operates through the following divisions: Enablers, BioActives, Sweeteners, Cultures, Genecor and Sales and Application Food Ingredients. The Enablers division develops, produces and markets emulsifiers, hydrocolloids, and tailored systems that enable food & beverage manufactureres to make appealing products. The BioActives division is comprised of the Cultures and Sweeteners divisions. It offers food cultures and protective solutions, speciality sweeteners, health ingredients, and microorganisms for agriculture and animal nutrition. The Genencor division develops innovative enzymes and bioproducts to reduce the environmental impact of the cleaning, textile, fuel, and chemical industries. The sales and Application food Ingredients division manages and budgets global key accounts. The company was founded in 1989 and is headquartered Copenhagen, Denmark

Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark.

Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark.

Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France.

7TM A/S performs research and development within biotechnology. It engages in clinical development of drugs focusing on obesity and gastrointestinal diseases. The company was founded by Thue Walter Schwartz, Anders Fink Vadsholt, Mette Kirstine Agger, Christian Ellebæk Elling, and Peter Moldt on January 1, 2000 and is headquartered in Hørsholm, Denmark.

Upfront Chromatography A/S develops a customized protein separation process. The firm offers industrial-scale customized separation solutions to isolate and purify soluble proteins from industrial process streams. Its core protein purification technology, rhobust, is applicable to industrial feed stocks. The company was founded by Allan Otto Fog Lihme in 1992 and is headquartered in Copenhagen, Denmark.

Vivostat A/S provides cardiac, thoracic and orthopaedic surgery medical devices. It offers vivostat system, an automated system for the on-site preparation and application of patient-derived fibrin sealant or platelet rich fibrin. Its products include Vivostat autologous fibrin sealant for various settings in surgical areas, transfusion centers, or blood banks and Vivostat platelet rich fibrin, which utilizes the patient's own blood to derive either a surgical sealant to prevent and stop bleedings, or a gel with a high concentration of growth factors that stimulates the healing of chronic wounds, as well as provides application devices. The compnay was founded in 2001 by Tom Bjerg Lauritzen and Niels Hvid and is headquartered in Alleroed, Denmark.

Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark.

nkt cables A/S operates as a global supplier to the energy sector. It designs, manufactures, and markets cables and solutions for the segments electricity infrastructure, building construction, railway, and automotive. The firm’s customers include third-party manufacturers, wholesalers, contractors, infrastructure, railway operators, and vehicles. The company was founded in 1922 and is headquartered in Asnæs, Denmark.

Novo Ventures (Novo Ventures) is a venture capital operating division of Novo Nordisk Fonden. It engages in investment activities. The firm was established in 1999, and is headquartered in Hellerup, Denmark.

Pharmascience, Inc. manufactures and distributes generic and drug products. It offers liquids, tablets, capsules, suppositories, powders, and ophthalmic. The company was founded by Morris Goodman and Ted S. Wise in 1983 and is headquartered in Montr?al, Canada.

Novo Seeds (Novo Seeds) is a venture capital operating division of Novo Nordisk Fonden. The firm was established in 2007, and is headquartered in Hellerup, Denmark.

Tekniikan Akatemia -säätiö sr, also known as Technology Academy Finland (TAF), is based in Helsinki, Finland. The CEOs of the Finnish company are Mikko Salaspuro and Ainomaija Susanna Haarla. TAF awards the €1 million Millennium Technology Prize and organizes associated events and initiatives. The private company provides an international meeting ground for corporate life, academia, and policymakers, and promotes Finland's position in the community. The Millennium Technology Prize is the world's most prestigious award for breakthrough innovations that improve the quality of people's lives.

The Danish National Advanced Technology Foundation promotes research and innovation by providing funds. It offers private companies and universities the funds and the framework for developing new and important technologies. The company was founded in 2005 and is headquartered in Copenhagen, Denmark.

Biosyntia ApS provides services in synthetic biology and metabolic engineering fields. It offers biocatalysts for fermentation of fine chemicals. The company was founded by Andreas Hougaard Laustsen, Morten Otto Alexander Sommer, and Hans Jasper Genee in 2012 and is headquartered in Copenhagen, Denmark.

iOnctura SA is a pre-clinical stage biopharmaceutical company focused on the research and development of novel immuno-oncology therapeutics for patients fighting cancer. The company was founded in June 2017 and is headquartered in Geneve, Switzerland.

Antag Therapeutics ApS develops peptide drugs for the treatment of dietary-related metabolic diseases. It develops drugs for obesity, diabetes, and non-alcoholic fatty liver disease. The company was founded by Alexander Sparre-Ulrich and Jens Juul Holst in 2017 and is headquartered in Copenhagen, Denmark.

ResoTher Pharma is a privately held clinical-stage biotech company based in Copenhagen, Denmark. ResoTher Pharma focuses on developing compounds that induce inflammatory resolution in cardiovascular diseases. The Danish company's lead compound, RTP-026, has shown to have a profound effect on reducing infarction size and restoring cardiac function to a pre-infarction level. ResoTher Pharma's mission is to create novel medicines that benefit patients in need by addressing unmet needs in CVD inflammation through endogenous immune regulatory pathways. The company was founded in 2016 by Thomas Jonassen and is privately owned by a group of prominent Danish investors.

Corbin Therapeutics, Inc. operates as a biotechnology platform.